[{"orgOrder":0,"company":"CareDx","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Inapplicable","moa":"||SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CareDx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CareDx \/ Vir Biotechnology","highestDevelopmentStatusID":"10","companyTruncated":"CareDx \/ Vir Biotechnology"},{"orgOrder":0,"company":"CareDx","sponsor":"TC BioPharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"CareDx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CareDx \/ TC BioPharm","highestDevelopmentStatusID":"8","companyTruncated":"CareDx \/ TC BioPharm"},{"orgOrder":0,"company":"CareDx","sponsor":"Eledon Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Inapplicable","moa":"||CD40","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"CareDx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CareDx \/ Eledon Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"CareDx \/ Eledon Pharmaceuticals"},{"orgOrder":0,"company":"CareDx","sponsor":"Eledon Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||CD40","graph1":"Immunology","graph2":"Phase II","graph3":"CareDx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CareDx \/ CareDx","highestDevelopmentStatusID":"8","companyTruncated":"CareDx \/ CareDx"},{"orgOrder":0,"company":"CareDx","sponsor":"CareDx","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Mycophenolate Mofetil","moa":"||Inosine-5\\'-monophosphate dehydrogenase (IMPDH)","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"CareDx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CareDx \/ CareDx","highestDevelopmentStatusID":"11","companyTruncated":"CareDx \/ CareDx"},{"orgOrder":0,"company":"CareDx","sponsor":"UT Southwestern Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Belatacept","moa":"||T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Undisclosed","graph2":"Phase IV","graph3":"CareDx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CareDx \/ CareDx","highestDevelopmentStatusID":"11","companyTruncated":"CareDx \/ CareDx"},{"orgOrder":0,"company":"CareDx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mycophenolate Mofetil","moa":"||Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"CareDx","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CareDx \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"CareDx \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by CareDx

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : The partnership aims to support ACHIEVE clinical trial using AlloCell to evaluate the efficacy and effectiveness of TCB008, an allogeneic gamma-delta T-cell therapy for patients with AML or MDS.

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          December 11, 2024

                          Lead Product(s) : OmnImmune,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : TC BioPharm

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 21, 2022

                          Lead Product(s) : Mycophenolate Mofetil,Inapplicable

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Collaboration agreement provides Eledon with access to CareDx’s best-in-class technologies, including the study to evaluate the safety, efficacy and pharmacokinetics of AT-1501 in de novo kidney transplant recipients.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          October 19, 2021

                          Lead Product(s) : Tegoprubart,Inapplicable

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Eledon Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          September 29, 2021

                          Lead Product(s) : Mycophenolate Mofetil,Mycophenolic Acid,Azathioprine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase IV

                          Recipient : University of California, Davis

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Presentation to focus on potential use of AT-1501 in kidney transplantation as well as research collaboration between Eledon and CareDx to help assess the efficacy of Eledon’s investigational AT-1501 for the prevention of rejection in upcoming kidney t...

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          April 11, 2021

                          Lead Product(s) : Tegoprubart,Inapplicable

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I

                          Recipient : Eledon Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : The ongoing trial is evaluating VIR-7831, a fully human anti-SARS-CoV-2 monoclonal antibody, for the early treatment of COVID-19 in adults at high risk of hospitalization.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          March 23, 2021

                          Lead Product(s) : VIR-7831,Inapplicable

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Vir Biotechnology

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          07

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          March 08, 2021

                          Lead Product(s) : Belatacept,Inapplicable

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase IV

                          Recipient : UT Southwestern Medical Center

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank